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Abstract: Aggressive natural killer cell leukemia (ANKL) is a
systemic NK-cell neoplasm, almost always associated with
Epstein-Barr virus (EBV). Rare cases of EBV-negative ANKL
have been described, and some reports suggested more indolent
behavior. We report the clinicopathologic, immunophenotypic,
and molecular characteristics of 7 EBV-negative ANKL. All
patients were adults, with a median age of 63 years (range 22 to
83 y) and an M:F ratio of 2.5:1. Five patients were White, 1
Black, and 1 Asian. All patients presented acutely, with fever (6/
7), cytopenias (6/7), and splenomegaly (4/7). Four patients had
lymphadenopathy, 4 had extranodal disease. Bone marrow in-
volvement was present in 5, with hemophagocytosis in 3. Pe-
ripheral blood was involved in 5 with the neoplastic cells
containing prominent azurophilic granules. By im-
munohistochemistry and/or ﬂow cytometry, the tumor cells
lacked surface CD3 and were positive for CD56 (7/7), CD2 (5/
5), CD8 (3/7), CD30 (4/5), and granzyme-B (6/6). They were
negative for CD4, CD5, bF1, TCRg, LMP1, and EBV-encoded
RNA. Polymerase chain reaction for TCRG clonality was pol-
yclonal. Mutational analysis revealed missense mutations in the
STAT3 gene in both cases studied. Median survival was 8 weeks
from the onset of disease. One patient received allogeneic bone
marrow transplant and is alive with no disease (follow-up
15mo). EBV-negative ANKL exists but is rare. It tends to occur
in older patients and is indistinguishable clinically and patho-
logically from EBV-positive ANKL, with a similar fulminant
clinical course. The high prevalence of Asian patients seen with
EBV-positive disease seems less evident with EBV-negative
cases.
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Aggressive natural killer (NK) cell leukemia (ANKL) isa rare, systemic neoplastic proliferation of NK cells,
described commonly in young adults of Asian eth-
nicity.1–3 Patients present acutely with fever, cytopenias,
liver failure, coagulopathy, and fulminant clinical course
with <2 months survival.4–6 Although a highly complex
karyotype with unbalanced chromosomal abnormalities
has been reported, no speciﬁc recurrent alterations have
been identiﬁed.4,7,8
Epstein-Barr virus (EBV) infection has been linked to
ANKL’s pathobiology and considered responsible for the
aggressive clinical features. However, occasional reports of
EBV-negative ANKL have been described,1,5,6,9–11 and a
slightly better outcome observed was attributed to an EBV-
negative status.6,11 Nevertheless, the limited number of the
cases reported hampers deﬁnitive conclusions. We identi-
ﬁed 7 cases of EBV-negative ANKL for which we reviewed
the clinicopathologic and immunophenotypic features. We
also studied 2 cases with available DNA for recurrent
mutations seen in T-cell and NK-cell neoplasms. Our re-
sults provide further insights into the pathogenesis of these
aggressive NK-cell neoplasms and their relationship to
EBV-positive counterparts.
MATERIALS AND METHODS
The pathology database of the Laboratory of
Pathology, National Cancer Institute, was searched for
NK/T-cell lymphomas/leukemias reported to be EBV
negative. Six such cases were identiﬁed in the Hema-
topathology consultation archives from 2000 to date. An
additional case was contributed by 1 of the coauthors
(C.A.T.-C.). The cases were reviewed by 3 of the authors
(E.S.J., K.A.G., A.N.), and a consensus in diagnosis
was reached. The clinicopathologic, immunophenotypic
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(including ﬂow cytometry), and molecular data were
analyzed. This study was approved by the Institutional
Review Board of the National Cancer Institute.
Immunohistochemistry and In Situ
Hybridization Studies
Immunohistochemistry (IHC) and in situ hybrid-
ization (ISH) studies were performed on available
formalin-ﬁxed paraﬃn-embedded tissue using the fol-
lowing antibodies: CD2, CD3, CD4, CD5, CD8, CD30,
CD56, granzyme-B, bF1, TCRg, and LMP1. The clones,
with dilution and source, are listed in Table 1. All cases
were tested for EBV-encoded RNA (EBER) by ISH.
EBER1 DNP probe supplied by Ventana on an auto-
mated stainer (Ventana-Benchmark XT, Tucson, AZ)
was used. ISH iView blue plus system with alkaline
phosphatase and nitroblue tetrazolium and 5-bromo-4-
chloro-3-indolyl phosphate substrate, with Fast Red as
contrast, was applied for visualization. To assess the ap-
propriate staining, a positive control was run with the
cases.
Molecular Studies
For T-cell receptor gamma (TCRG) rearrangement,
DNA was extracted from whole-tissue formalin-ﬁxed
paraﬃn-embedded tissue sections and ampliﬁed by pol-
ymerase chain reaction, as published previously.12 A
single multiplexed polymerase chain reaction was done
with primers directed against all known Vg family mem-
bers, and the Jg1/2, JP1/2 and JP joining segments. The
product was analyzed by capillary electrophoresis on an
ABI 3130xl Genetic Analyzer (Applied Biosystems, Fos-
ter City, CA).
Mutational Analysis
Two cases with available DNA were analyzed for
somatic mutations using a targeted next-generation se-
quencing (NGS) strategy. The mutation panel included
regions of 38 genes previously reported to be mutated in
T-cell lymphomas, as well as regions of genes involved in
T-cell signaling focused on the JAK/STAT signaling
pathway. The amplicon libraries were generated with 2
custom primer pools (total 227 amplicons) and were se-
quenced on an Ion Torrent Personal Genome Machine
(PGM) (Life Technologies). The NGS methods and the
list of the genes analyzed were recently published12
RESULTS
Clinical Features
The demographic, clinical, and outcome data are
detailed in Table 2. All patients were adults, with a me-
dian age of 63 years (range 22 to 83 y) and an M:F ratio of
2.5:1. Five patients were White, 1 Black, and 1 Asian. No
patients were identiﬁed as being of Hispanic or Native
American heritage. All patients presented acutely, with
<1-month duration of symptoms. One patient (case 2)
had a 9-year history of lymphoplasmacytic lymphoma/
Waldenstrom macroglobulinemia and was diagnosed
with ANKL just after completion of the sixth cycle of
Rituxan, Fludarabine, and Cytoxan for recurrent disease.
Another patient (case 6) with hepatitis C, chronic kidney
disease, and intravenous drug abuse had a 1-year history
of lower extremity ulcers, which were thought clinically to
be a manifestation of cryoglobulinemia and vasculitis.
Six patients presented with fever, 5 with night
sweats, and 4 with lower extremity edema and ascites.
Three patients had skin lesions manifesting as rash (case
1) or patches, ulcerated plaques, and nodules (cases 6, 7).
One patient had disseminated intravascular coagulation
(case 1). Clinical examination and computed tomog-
raphy/positron emission tomography scan showed sple-
nomegaly in 4 and lymphadenopathy in 4 patients. One
patient had extensive omental disease (case 3), and 1
showed foci of increased metabolic activity in the sinuses,
pericardium, pancreas, and gastric wall (case 6). Four
patients had abnormal liver function tests and/or hep-
atomegaly. Except 1, all showed various degrees of cy-
topenias; none showed leukocytosis.
Three patients received CHOP and 1 a CHOP-like
regimen as initial therapy. In addition, case 1 received
EPOCH, Campath, and high-dose cytosine arabinoside,
and case 7 received Bortezomib, with no evident response.
Five patients died within 2 months and 1 in 7 months
from the onset of symptoms (median survival 8wk). One
patient (case 5) who received 6 cycles of SMILE13 and a
matched unrelated donor bone marrow transplant is alive
with no disease (follow-up 15mo).
Pathologic Findings
A summary of the morphologic, IHC, and molec-
ular ﬁndings is shown in Table 3, and representative im-
ages are displayed in Figure 1. Bone marrow biopsies
were available for evaluation in 5 cases; cellularity ranged
from hypercellular (cases 1, 4) to hypocellular (case 2).
Core biopsies showed an atypical lymphocytic inﬁltrate
with an interstitial pattern, which varied in extent from
subtle (cases 2, 7) to extensive (cases 1, 4). In addition,
loose lympho-histiocytic aggregates (cases 2, 3) and a rich
granulomatous background (case 4) were seen. Normal
hematopoiesis was overall reduced with progressive ma-
turation present. Hemophagocytic activity was noted in 3
cases and most prominent in case 2.
The liver biopsy in case 2 showed atypical portal
lympho-histiocytic aggregates with scattered abnormal
lymphocytes in the parenchyma and multiple foci of
TABLE 1. Antibodies Used in the Immunophenotypic Analysis
Antigen Clone Dilution Source
CD2 AB75 1:160 Novocastra
CD3 Polyclonal 1:100 Dako
CD4 1F6 1:40 Novocastra
CD5 4C7 1:100 Novocastra
CD8 C8/144B 1:50 Dako
CD30 1G12 1:50 Novocastra
CD56 1B6 1:50 Novocastra
bF1 8A3 1:20 Endogen
TCRg g3.20 1:100 Thermo Scientiﬁc
Granzyme-B GrB-7+D170 1:100 Monosan
LMP1 CS1-4 1:400 Dako
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conﬂuent hepatocellular necrosis without a zonal dis-
tribution pattern. By contrast the liver involvement in
case 7 was predominantly intrasinusoidal. A lymph node
biopsy (case 5) showed diﬀuse eﬀacement by tumor cells,
which also percolated into surrounding adipose tissue. A
prominent starry sky pattern with tingible body macro-
phages was seen. Skin biopsies (cases 6, 7) showed a
patchy, atypical dermal lymphoid inﬁltrate with a peri-
vascular and interstitial pattern of inﬁltration. Apoptotic
bodies were present, but the lesions lacked overt necrosis.
The omental biopsy (case 3) demonstrated a panniculitis-
like lymphoid inﬁltrate, with the presence of rimming by
the atypical lymphocytes.
Cytologically, in 6 cases the tumor cells were mo-
notonous, medium-sized with a moderate amount of pale
cytoplasm, round or irregular nuclei, ﬁnely clumped
chromatin, and small nucleoli. Case 4 showed atypical
cells ranging in cell size with some large pleomorphic
forms, dense chromatin, and moderate to abundant pale
cytoplasm. The atypical cells in this case were admixed
with histiocytes. Peripheral blood smears, available for 5
patients, showed atypical lymphoid cells with irregular
nuclei and basophilic cytoplasm with prominent azur-
ophilic granules. The same cytologic features were also
observed in the bone marrow aspirates (cases 1, 2, 3, 4, 7)
and touch preps obtained from the omental mass (case 3).
TABLE 2. Demographic Features, Presentation, Management, and Outcome ANKL, EBV
Case
No.
Age/
Sex Ethnicity
Clinical
Presentation Fever
Night
Sweats Splenomegaly
Lymphaden-
opathy Cytopenias Therapy Outcome
Duration
Disease/
Follow-up
1 22/F White Acute onset, skin
rash, edema, ascites,
hepatomegaly,
jaundice, abnormal
hepatic & kidney
function,
coagulopathy, high
LDH
 + + Abdomen,
chest
Thrombocy-
topenia
CHOP,
EPOCH,
Campath+
Cytosine
arabinoside
DoD 8wk
2 73/M White Fever and weakness,
focal liver
abnormalities
+    Pancytopenia N/A DoD 7wk
3 52/M Asian 3-4 wk history of
abdominal
distension, chills,
weakness, ascites,
pleural eﬀusion,
hypoxemia,
abnormal liver
function
+ + + Mediastinum  1CHOP DoD 8wk
4 83/F White 4wk history of fever,
episodic confusion
+    Pancytopenia 1CHOP DoD 8wk
5 64/M White Acute onset, nausea,
vomiting, diarrhea
+ + + Diﬀuse Pancytopenia 6SMILE,
allogeneic
MUD BMT
Alive, no
disease
15mo (8mo
after
transplant)
6 63/M Black Acute onset, chest
pain, skin plaques/
nodules, edema,
sinus changes,
pericardium,
pancreas, gastric
wall. 1 yr history of
lower extremity
ulcers, Hep C,
IVDA, CKD.
+ +  Diﬀuse Anemia Palliative Care DoD 8wk
7 60/M White Acute onset, skin
rash/patches/
plaques/nodules,
edema, ascites,
fever, chills, night
sweats, weakness,
weight loss,
hepatomegaly, high
LDH, abnormal
kidney function
+ + +  Pancytopenia 2Hyper-
CVAD,
Bortezomib,
intrathecal
CHT
DoD 7mo
CHOP indicates cyclophosphamide, adriamycin, vincristine, prednisone; CHT, chemotherapy; CKD, chronic kidney disease; CVAD, cyclophosphamide, vincristine,
doxorubicin, dexamethasone; DoD, died of disease; EPOCH, etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin; F, female; Hep, hepatitis C; IVDA,
intravenous drug abuse; LPL, lymphoplasmacytic lymphoma; M, male; MUD BMT, matched unrelated donor bone marrow transplant; SMILE, dexamethasone,
methotrexate, ifosfamide, L-asparaginase, etoposide.
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Immunophenotype
The IHC stains and the ﬂow cytometry studies
(available in 6/7 cases) demonstrated an absence of sur-
face CD3 (Fig. 2). The cells expressed CD56 (7/7), CD2
(5/5), CD8 (3/7), granzyme-B (6/7), and CD30 (4/5). They
were negative for CD4, CD5, bF1, TCRg, and LMP1.
Two cases analyzed showed absence of CD57 by ﬂow
cytometry. All cases were negative for EBER by ISH.
T-cell Receptor Gene Rearrangement and
Mutational Analysis
Polyclonal TCRG rearrangement was present in all
4 cases analyzed with adequate DNA. One case showed
no ampliﬁcation products.
Two cases (5 and 6) were analyzed with a custom
NGS mutation panel. Case 5 was found to have STAT3
(c.1919A>T; p.Tyr640Phe, allele frequency [AF] 20.3%)
and PTPN2 (c.671 G>T, p.Gly224Val, AF 24.2%)
mutations. Case 6 showed a missense mutation in STAT3
(c.1981 G>T, p.Asp661Tyr, AF 41.9%) but diﬀered
from that seen in case 5.
DISCUSSION
ANKL is an extremely rare entity with <200 cases
published to date.2,4,5 It has a strong association with
EBV infection, which is considered part of disease deﬁ-
nition. Like other EBV-positive T-cell and NK-cell neo-
plasms, it has a higher incidence in Asia and is also
encountered among indigenous populations in the
Americas. Since its description by Fernandez et al in
1986,14 sporadic EBV-negative ANKL cases have been
reported. EBV negativity has been speculated to correlate
with a less aggressive clinical outcome.11,15 However, the
rarity of the reported cases precludes ﬁrm conclusions. In
the current study, we describe the clinicopathologic fea-
tures, clinical management, and outcome in 7 ANKL
EBV-negative cases and compare the ﬁndings with those
reported for ANKL EBV positive.
ANKL EBV negative is clinically comparable to
ANKL EBV positive with a similar clinical presentation
and course. However, patients with EBV-negative disease
tend to be older (median age 63 y) compared with patients
with EBV-positive ANKL (median age approximately 36
to 38 y).2,4,16 The older age at onset might correlate with
other epidemiological features. Interestingly, 5 of our
patients were White (not of Hispanic heritage), providing
further epidemiological contrast with ANKL EBV-
positive ANKL. Similar to EBV-positive ANKL, our
patients presented acutely with fever, splenomegaly, and
cytopenias.2,4,5 Besides, bone marrow and peripheral
blood involvement, lymphadenopathy was a common
feature observed in 57% of cases, similar to what has been
reported for EBV-positive disease.1,2,4 Historically, the
terminology of “leukemia/lymphoma” has been used for
this disease,17 reﬂecting its systemic nature and extensive
multiorgan involvement.8,17
We observed hepatomegaly and/or abnormal liver
function tests in 57% of patients. It has been shown that
besides tumor cell involvement, malignant NK cells con-
stitutively express FASL, which triggers apoptosis of
hepatocytes or other cell types that express FAS.18 In-
deed, in case 2, we observed multifocal areas of necrosis
and a high rate of apoptosis of individual hepatocytes.
Furthermore, similar to EBV-positive cases, there is risk
for involvement of the central nervous system; 1 of our
TABLE 3. Morphology, Immunophenotype, EBER-ISH, and T-cell Clonality by PCR in ANKL, EBV
Case
No.
Biopsy Site
(s)
Tumor cell
Morphology HPS CD2 CD3 CD4 CD8 CD5 CD7 CD56 CD30 bF1 TCRc GZB LMP1 EBER
PCR
TRG
1 Bone
marrow
Monotonous, medium
size
 na + c na +  na + na   +   No
amp
2 Bone
marrow,
Liver, PB
Monotonous, medium
size, azurophilic
granules
+ na + c    na + + na  +   PC
3 Bone
marrow,
omentum,
PB
Monotonous, small-
medium size,
azurophilic granules
+ + + c  + na + + na na na na na  na
4 Bone
marrow
Pleomorphic, range in
cell size
 +   +
f,w
  +  na  + na  na
5 LN axilla,
PB
Monotonous, medium
size, azurophilic
granules
+ + + c     + f +   +   PC
6 Skin, PB Monotonous, medium
size, azurophilic
granules
 + +c     + +w   +   PC
7 Skin, liver,
bone
marrow,
PB
Monotonous, medium
size, azurophilic
granules
 +      + +f   + na  PC
BM indicates bone marrow; c, cytoplasmic; f, focal; GZB, granzyme-B; HPS, hemophagocytic syndrome; LN, lymph node; Ly, lymphocytes; na, not available; No amp,
no ampliﬁcation; PB, peripheral blood; PC, polyclonal; PCR, polymerase chain reaction; s-surface; TRG, T-cell receptor g chain gene; w, weak.
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FIGURE 1. Morphologic, immunophenotypic, and genotypic features of EBV-negative ANKL. A, Bone marrow biopsy contains
atypical interstitial infiltrate composed of medium-sized lymphocytes with fine chromatin and abundant pale cytoplasm (case 3).
B, A lymph node is diffusely infiltrated by atypical lymphocytes with abundant apoptotic debris in tingible body macrophages.
The tumor cells on touch prep were medium in size with round/irregular nuclei, pale cytoplasm, and easily identifiable mitoses (B,
inset) (case 5). C, The bone marrow from case 4 contains more pleomorphic lymphocytes ranging in cell size, with reactive
histiocytes in the background. D, A touch prep from an omental mass showed cytologically atypical lymphocytes with pale
cytoplasm containing prominent azurophilic granules (case 3). E, Circulating cells with prominent azurophilic granules are present
(case 5). By IHC the cells express cytoplasmic CD3 (F), CD56 (G), and granzyme-B (H). I, Bone marrow (case 2) shows reduced
hematopoiesis and numerous histiocytes with hemophagocytosis. J, All cases were negative for EBER by ISH (case 3). K, Pol-
ymerase chain reaction for TCRG showed a polyclonal rearrangement pattern (case 5).
Am J Surg Pathol  Volume 41, Number 1, January 2017 EBV-negative Aggressive NK-cell Leukemia/Lymphoma
Copyright r 2016 Wolters Kluwer Health, Inc. All rights reserved. www.ajsp.com | 71
Copyright r 2016 Wolters Kluwer Health, Inc. All rights reserved.
patients presented with episodic confusion. This feature
can be attributed to CD56/Neuronal Cell Adhesion
Molecule (NCAM) expression on the tumor cells,
which leads to cell adhesion and recognition of other cell
types expressing NCAM, such as brain, nerve, and
muscle.2,19
ANKL EBV negative is a rapidly progressive dis-
ease with high mortality within weeks of diagnosis. Five
of our patients died within 8 weeks from the onset of
symptoms; the only long-term survivor received an allo-
geneic bone marrow transplant. A similarly aggressive
outcome was reported by Suzuki et al5 in 2 other patients
with EBV-negative ANKL. However, a few case reports
encompassing 4 patients described longer survival with a
range from 11 months to 4 years.9,10,15 It has been
speculated that lack of EBV and its upregulation of the
multidrug resistance genes6 might account for an initial
therapeutic response and the slightly better survival ob-
served.15 The favorable outcome of our singular patient
who underwent allogeneic bone marrow transplant points
to a possible role of this management to control the dis-
ease. Newer regimens containing asparaginase have also
proved eﬀective in other EBV-positive NK-cell neoplasms
and may be suitable to explore.13
No morphologic or immunophenotypic features
reliably discriminate between EBV-positive and EBV-
negative ANKL. Five of our cases showed blast-like
morphology with monotonous, medium-sized lympho-
cytes with ﬁne chromatin and coarse azurophilic granules;
only 2 cases contained pleomorphic cells, with hyper-
chromatic nuclei. A similar cytologic spectrum has been
described in EBV-positive ANKL.4 In addition, the ob-
served immunophenotype with expression of CD2 and
CD56 and lack of surface CD3 and CD7 is similar to that
of EBV-positive ANKL.8 Clinical features aid in the
diﬀerential diagnosis with extranodal NK/T-cell lym-
phoma, nasal type, which presents with more localized
extranodal disease, lacking the systemic dissemination of
both EBV-positive and EBV-negative ANKL. The pres-
ence of large geographic areas of necrosis is a helpful
pathologic feature, not seen in ANKL.20
Prompt and accurate diagnosis of EBV-negative
ANKL is required. The diagnosis is often delayed due to
the absence of EBV, a feature leading to all of the cases
being submitted for consultation. On the basis of the
acute clinical course, we excluded the possibility of
chronic lymphoproliferative disorder of NK cells, an in-
dolent process immunophenotypically similar to EBV-
negative ANKL. More challenging is the distinction of
EBV-negative ANKL from hepatosplenic T-cell lym-
phoma (HSTL) due to signiﬁcant clinical, morphologic,
and immunophenotypic overlap, as seen for case 7, ini-
tially suspected as HSTL in the liver biopsy. Lack of
surface CD3 by ﬂow cytometry is useful in assigning an
NK lineage; however, this feature, although rare, has
been described in HSTL at relapse as well as in a de novo
FIGURE 2. Flow cytometric analysis of EBV-negative ANKL. The atypical cells are negative for surface CD3, positive for CD56 and
CD2, and negative for CD4, CD8, CD7, and CD5 (not shown) (case 5).
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case reported recently by Kapur et al.4 Abnormalities of
chromosome 77 and trisomy 8,4 typical of HSTL, have
been described in exceptional cases of EBV-positive
ANKL, but no case with both abnormalities have been
reported. In case 7 multiple features favor EBV-negative
ANKL over HSTL, including systemic disease with
lymphadenopathy, skin lesions, interstitial bone marrow
involvement, and lack of clonal TCR gene rearrangement.
Little is known about the molecular pathogenesis of
either EBV-positive or EBV-negative ANKL. A recent
report from Gao et al8 found evidence of STAT5B mu-
tations in 1/5 cases studied of EBV-positive ANKL, but
all 5 cases were negative for mutations in STAT3. We
were able to identify STAT3 mutations by targeting se-
quencing in both EBV-negative cases analyzed, although
diﬀerent hotspots were seen (Y640F [case 5] and D661V
[case 6]). The same type of STAT3 mutation has been
identiﬁed in T-cell and NK-cell large granular lymphocyte
(LGL) leukemia,21,22 where it has been shown to increase
the transcriptional activity of STAT3 with upregulation
of its downstream targets.23 These observations suggest
that EBV-negative ANKL might arise by transformation
from NK-cell LGL, a phenomenon that has been re-
ported rarely.24 However, none of our patients had clin-
ical evidence of prior low-grade disease. Cytologic atypia,
seen in all of our cases of EBV-negative ANKL, is one
key to this critical diﬀerential diagnosis. In addition, 3
cases showed evidence of hemophagocytic activity, which
is a common feature of both EBV-positive and EBV-
negative ANKL, but is not seen in NK-cell LGL.20,25
Notably, activating mutations in STAT3 also have
been recently identiﬁed in 26.5% of extranodal NK/T-cell
lymphoma nasal type26 and regarded as an intrinsic
mechanism of STAT3 activation in addition to an ex-
trinsic one elicited by the EBV proteins.26 Besides a
STAT3 missense mutation, case 5 also harbored a mu-
tation in the PTPN2. PTPN2 (protein tyrosine phos-
phatase nonreceptor type 2) is a tumor-suppressor gene
and a negative regulator of JAK/STAT pathway.27 Bial-
lelic inactivation of PTPN2 by deletion of the entire gene
locus or by mutation has been identiﬁed with low
frequency in T-cell acute lymphoblastic leukemia and
peripheral T-cell lymphoma not otherwise speciﬁed.27,28
Although no additional functional studies are available, it
is likely that a combination of PTPN2 inactivation and
STAT3 mutation would result in uncontrolled activation
of the JAK/STAT pathway. Our data provide further
evidence for deregulation of the JAK/STAT pathway in
NK-derived malignancies, independent of EBV status.
In conclusion, we provide further evidence for the
existence of EBV-negative AKNL, which shares most
clinical and pathologic features with EBV-positive ANKL,
including an aggressive clinical course. The high incidence
of non-Asian patients in this Western series suggests that
EBV-negative ANKL may not share the racial predi-
lections of the EBV-positive cases. Deregulation of the
JAK/STAT pathway appears to play an important role, as
it does in other cytotoxic T-cell and NK-cell malignancies.
Future studies to compare EBV-positive and EBV-negative
ANKL would be of interest to better assess their relation-
ship and common pathobiology.
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